Shenyang Tianfeng Bio-Pharm Co., Ltd.

Have updates for this profile? Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Shenyang Tianfeng Bio-Pharm Co., Ltd. - overview

Established

2005

Location

Shenyang, Liaoning, China

Primary Industry

Biotechnology

About

Based in Shenyang, China and founded in 2005, Shenyang Tianfeng Bio-Pharm Co. , Ltd. provides phospholipid-based ingredients for the healthcare industry. The company was established to develop high end natural phospholipids and has since expanded its capabilities to include bioconversion technologies and custom application solutions.


In January 2026, the company closed a series B funding from Zhongtian Liaochuang Investment. The company works with pharmaceutical manufacturers, food producers, and cosmetic companies to provide specialized ingredient solutions. Additionally, the firm offers custom formulations and application technology services to meet specific client requirements. The company’s revenue is generated by the direct sale of phospholipid products to industrial clients.


The company plans to use the recent series B funding to expand its production lines and enhance its market presence.


Current Investors

Shenyang Biomedical Venture Fund, Zhongtian Liaochuang Investment

Primary Industry

Biotechnology

Sub Industries

Food, Biopharmaceuticals

Website

www.taxol.com.cn/

Verticals

Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.